Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Advaxis Begins HPV-Cancer Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Advaxis Begins HPV-Cancer Trial

Tests immunotherapy against head and neck cancer caused by HPV

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Advaxis and the Icahn School of Medicine at Mount Sinai (ISMMS) will begin a Phase I/II study of ADXS-HPV in 25 patients with Human Papilloma Virus (HPV)-positive head and neck cancer. This trial will be the first study to evaluate the effects of ADXS-HPV in patients when they are initially diagnosed with HPV-associated head and neck cancer, prior to receiving any chemotherapy or radiation. This study will be an important first step toward understanding ADXS-HPV’s potential to treat this type of cancer before chemotherapy and/or radiation and its potential to reduce the need for these treatments.

ADXS-HPV is Advaxis’ lead immunotherapy product candidate for the treatment of HPV-associated cancers and has achieved proof-of-concept, demonstrating clinical activity and a manageable safety profile in patients with recurrent cervical cancer in a recently completed Phase II study. Advaxis received Orphan Drug Designation from the FDA for ADXS-HPV for HPV-associated head and neck cancer in early November.

This non-randomized investigator-initiated study has been designed to evaluate the safety and immunogenicity of ADXS-HPV in patients with HPV-positive stage II-IV squamous cell carcinoma of the oropharynx (OPCSC). In this study, 15 patients will receive ADXS-HPV treatment followed by ablative transoral robotic surgery (TORS), and 10 patients will serve as the control group and receive only TORS. TORS is FDA-approved for head and neck cancer and is considered to be the standard of care therapy for OPCSC in appropriate patients.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics